INTRODUCTION AND OBJECTIVES: Transurethral resection of the prostate (TURP), using electro-cautery, is the commonest surgical procedure for benign prostatic obstruction (BPO). Thuliumlaser transurethral vaporesection of the prostate (ThuVARP) is a relatively new technique which vaporises and resects the prostate similarly to TURP (e.g. resectoscope hand-movement) with histology also being available. The limited literature suggests advantages of laser techniques in terms of length of stay and bleeding. This NIHRfunded study aimed to determine whether ThuVARP is equivalent to TURP for BPO treatment.
METHODS: This randomized controlled, parallel-group, blinded phase III trial was conducted in seven UK centres. Men presenting with voiding LUTS or urinary retention secondary to BPO were randomized to TURP or ThuVARP. The co-primary outcomes were the IPSS and maximum urinary flow rate (Qmax) at 12 months. Secondary outcomes included complications (Clavien-Dindo), healthcare costs and patient experiences.
RESULTS: Overall, 410 men were randomized (205/arm). IPSS scores reduced equally for both procedures with a small benefit for TURP in Qmax (Table 1) . Surgical complications, transfusion rates and hospital stay were similar for both procedures. Patient experiences
